Medical Management of Endometrial Polyps in Premenopausal Women with Abnormal Uterine Bleeding
Oral progesterone tablets are not a proven or recommended medical treatment for endometrial polyps in premenopausal women; hysteroscopic polypectomy remains the definitive management for symptomatic polyps, while conservative observation is appropriate only for asymptomatic cases.
Diagnostic Confirmation Required First
Before considering any treatment, confirm the diagnosis and assess malignancy risk:
- Transvaginal ultrasound is the primary diagnostic tool, though hysteroscopy with direct visualization is the gold standard for diagnosis 1
- Saline infusion sonohysterography has 96-100% sensitivity for detecting focal endometrial pathology and 97% accuracy in distinguishing polyps from submucosal fibroids 2, 3
- Endometrial biopsy is mandatory if the patient has risk factors including age >45 years, obesity, diabetes, hypertension, unopposed estrogen exposure, or tamoxifen use 3
Treatment Algorithm Based on Symptoms and Risk
For Symptomatic Premenopausal Women (Abnormal Uterine Bleeding)
Hysteroscopic polypectomy is recommended for all women with abnormal uterine bleeding 1, 4. This is the standard of care because:
- Complete polyp removal under hysteroscopic guidance provides both symptom resolution and definitive histopathological diagnosis 1
- The overall malignancy risk is approximately 3%, but increases with abnormal bleeding 1, 5
- Office endometrial biopsy has a 10% false-negative rate and may miss focal lesions 6, 3
For Asymptomatic Premenopausal Women
Conservative management with observation is an appropriate option 1, 4, as:
- Approximately 25% of polyps resolve spontaneously 1
- Malignancy risk is minimal in asymptomatic premenopausal women 5
- Follow-up ultrasound should be performed after 3 months to assess for regression 7
Evidence on Oral Progesterone Tablets
There is no proven preventative or medical treatment for endometrial polyps using oral progesterone 1. The evidence base is extremely limited:
- One retrospective study examined subcutaneous progesterone (not oral tablets) administered during the luteal phase (25 mg for 7 days for 3 cycles), showing a 47.5% regression rate versus 12.5% in controls 7
- This was a small retrospective study requiring prospective validation 7
- Injectable medroxyprogesterone acetate is specifically NOT recommended for dysfunctional uterine bleeding due to its prolonged action and unpredictable withdrawal bleeding; oral therapy is preferred for these conditions 8
Medical Management of Abnormal Uterine Bleeding (Not Polyp-Specific)
If the patient has abnormal uterine bleeding from other causes or while awaiting polypectomy:
- Levonorgestrel-releasing IUD is the most effective first-line medical treatment, reducing menstrual blood loss by 71-95% 9
- Combined hormonal contraceptives are effective for ovulatory dysfunction bleeding 9
- Oral progestins can be administered for 21 days per month for menstrual blood loss reduction in women with cyclic heavy bleeding 9
- Avoid NSAIDs and tranexamic acid in patients with cardiovascular disease due to MI and thrombosis risk 2, 9
Critical Pitfalls to Avoid
- Do not rely on endometrial biopsy alone to rule out polyps, as it has variable sensitivity for focal lesions 9
- Do not use oral progesterone as definitive treatment for symptomatic polyps, as there is no evidence supporting this approach 1
- Do not defer polypectomy in symptomatic patients hoping for spontaneous regression, as this delays definitive diagnosis and symptom relief 1, 4
- Ensure histopathological examination of all removed polyps to exclude malignancy, particularly in postmenopausal women with bleeding where malignancy risk reaches 7.2% 5
When to Refer to Gynecology
Immediate referral is indicated when 3:
- Endometrial sampling shows hyperplasia or malignancy
- Medical management fails
- Persistent abnormal bleeding despite negative initial workup